CA2428438C - Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases - Google Patents

Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases Download PDF

Info

Publication number
CA2428438C
CA2428438C CA2428438A CA2428438A CA2428438C CA 2428438 C CA2428438 C CA 2428438C CA 2428438 A CA2428438 A CA 2428438A CA 2428438 A CA2428438 A CA 2428438A CA 2428438 C CA2428438 C CA 2428438C
Authority
CA
Canada
Prior art keywords
leu
ser
glu
lys
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2428438A
Other languages
English (en)
French (fr)
Other versions
CA2428438A1 (en
Inventor
Christophe Echeverri
Pierre Goenczy
Anthony Hyman
Steven Jones
Karen Oegema
Matthew Kirkham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenix BioScience GmbH
Original Assignee
Cenix BioScience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenix BioScience GmbH filed Critical Cenix BioScience GmbH
Publication of CA2428438A1 publication Critical patent/CA2428438A1/en
Application granted granted Critical
Publication of CA2428438C publication Critical patent/CA2428438C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2428438A 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases Expired - Fee Related CA2428438C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24675000P 2000-11-09 2000-11-09
US60/246,750 2000-11-09
PCT/EP2001/013034 WO2002038805A2 (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
CA2428438A1 CA2428438A1 (en) 2002-05-16
CA2428438C true CA2428438C (en) 2012-09-25

Family

ID=22932039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2428438A Expired - Fee Related CA2428438C (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Country Status (9)

Country Link
US (1) US7368248B2 (enExample)
EP (1) EP1334123B1 (enExample)
JP (1) JP2004526421A (enExample)
AT (1) ATE405585T1 (enExample)
AU (2) AU2002224838B9 (enExample)
CA (1) CA2428438C (enExample)
DE (1) DE60135482D1 (enExample)
DK (1) DK1334123T3 (enExample)
WO (1) WO2002038805A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
WO2005049846A2 (en) * 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US9708619B2 (en) 2005-09-20 2017-07-18 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRNA
BRPI0809130A8 (pt) 2007-03-21 2021-11-03 Brookhaven Science Ass Llc Composições combinadas hairpin-antissenso e métodos para modulação da expressão
CA2784783C (en) 2009-12-18 2021-07-20 Novartis Ag Organic compositions to treat hsf1-related diseases
CA2789125A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Also Published As

Publication number Publication date
AU2002224838B2 (en) 2006-07-27
JP2004526421A (ja) 2004-09-02
CA2428438A1 (en) 2002-05-16
DE60135482D1 (de) 2008-10-02
EP1334123A2 (en) 2003-08-13
US20040048277A1 (en) 2004-03-11
AU2483802A (en) 2002-05-21
ATE405585T1 (de) 2008-09-15
US7368248B2 (en) 2008-05-06
EP1334123B1 (en) 2008-08-20
WO2002038805A8 (en) 2007-07-05
AU2002224838B9 (en) 2007-02-08
WO2002038805A3 (en) 2003-02-13
WO2002038805A2 (en) 2002-05-16
DK1334123T3 (da) 2009-01-12

Similar Documents

Publication Publication Date Title
CA2428438C (en) Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
FI121366B (fi) Uusia siiliperäisiä polypeptidejä
Zheng et al. The deaf jerker mouse has a mutation in the gene encoding the espin actin-bundling proteins of hair cell stereocilia and lacks espins
ES2625316T3 (es) Neuquinasa, una proteína corriente abajo de neuregulina
JP2003516124A (ja) 標的とした遺伝的干渉の手段としてのrna干渉経路遺伝子
AU2002224838A1 (en) Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
Tu et al. Membrane-associated collagens with interrupted triple-helices (MACITs): evolution from a bilaterian common ancestor and functional conservation in C. elegans
Ochi et al. CCDC61/VFL3 is a paralog of SAS6 and promotes ciliary functions
US6627746B1 (en) Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
AU2002227917B2 (en) Genes required for viability and/or reproduction in C. elegans and their use in the development of anti-nematode agents
AU2004271725B2 (en) The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferative diseases
AU2002227917A1 (en) Genes required for viability and/or reproduction in C. elegans and their use in the development of anti-nematode agents
WO2001096371A2 (en) Adipose-related gene
Zhou et al. The gene structure and promoter region of the vaccine target aminopeptidase H11 from the blood-sucking nematode parasite of ruminants, Haemonchus contortus
JP2002223768A (ja) ヒトミトコンドリア蛋白質とこの蛋白質をコードするポリヌクレオチド
EP1682663A2 (en) The use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases
JP4136612B2 (ja) タンパク質PGC−1vとその遺伝子
WO2005026388A2 (en) The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases
Ketchum Molecular analysis of the Drosophila melanogaster cytoplasmic myosin heavy chain
Topf Investigations on the function of ten-1 during embryonic development in Caenorhabditis elegans.
Green A Molecular Analysis of the Tissue Polarity Gene Prickle and Associated Transcripts in Drosophila Melanogaster
WO2000049048A1 (en) Ndae1 - a new bicarbonate transporter
JP2002238578A (ja) ラットedg7受容体

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151109